MRG-229 / Viridian Therap - LARVOL DELTA

Reactivation of miR-29 Mitigates Epigenetic Deregulation and Tumor Progression in Advanced Prostate Cancer (EACR 2025) - "We hypothesized that restoring miR-29 expression could reverse aberrant epigenetic regulation, potentially reactivating epigenetically-silenced tumor-suppressive pathways.Material and To test this hypothesis, androgen-independent prostate cancer cell lines (PC3, DU145, LNCaP-abl, 22Rv1) were treated with miR-29 mimics for isoforms a, b, and c. Cells were collected at multiple time points (48-192 hours), followed by transcriptomic analyses, real-time PCR, Annexin V-PI apoptosis and migration assays to evaluate gene expression changes and functional outcomes.Result and Transcriptomic analysis following miR-29 mimic in PC3 cells revealed substantial gene expression changes, notably increased pro-apoptotic mediators and decreased expression of genes involved in cell invasion and extracellular matrix remodeling... Collectively, these findings position miR-29 reactivation as a potential therapeutic strategy to reverse epigenetic dysregulation and overcome treatment..."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ANXA5 • MIR29A

Ratio of miRNA-29 to miRNA-199 expression coordinates mesenchymal stem cell repair of bleomycin-induced pulmonary injury. (PubMed, Mol Ther Nucleic Acids) - "Our previous work demonstrated the anti-fibrotic effects of infusion of adipose-derived mesenchymal stem cells (ASCs) to prevent or repair bleomycin (BLM)-induced lung injury. In vitro and ex vivo experiments using double-transfected mouse or human myofibroblasts (miR-29 mimic, and miR-199 inhibitor) confirmed that alterations of these miRNAs regulate downstream effectors of fibrosis. These data suggest that alteration of the ratio of anti-fibrotic to fibrotic miRNAs and increase in telomere length are critical mechanisms of ASC-mediated repair of BLM-induced pulmonary fibrosis."

Journal • Fibrosis • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • MIR29A • TERT • TNFA

Soluble ST2 release from airway epithelial cells is suppressed by house dust mite and the miRNA-29 family (ERS 2024) - "Primary human bronchial epithelial cells (HBECs) were stimulated with HDM or transfected with miR-29 mimics or inhibitors and the secretion of sST2 was measured after 24 or 48h in cell supernatants using ELISA... Suppression of the IL-33 decoy receptor sST2 by HDM and miR-29s in airway epithelial cells may promote IL-33/ST2-signalling in the airways. Thus, our data suggest a potential role for miR-29s in exacerbating IL-33-dependent allergic airway inflammation."

Asthma • Immunology • Inflammation • Respiratory Diseases • IL33

The Mechanism of miR-29 in Bladder Cancer Released by Exosomes into Brain Microglia to Promote M2 Polarization and Angiogenesis in Brain Metastasis of Bladder Cancer. (PubMed, Altern Ther Health Med) - "Bladder cancer cells T24 were transfected with miR-29 NC, mimic, or neferine and divided into miR-29-NC group, miR-29-mimic group, miR-29-NC-neferine group, and miR-29-mimic-neferine group...In vivo experiments demonstrated that miR-29 could promote the cell volume of bladder cancer cells and increase the number of blood vessels in bladder cancer cells, while neferine could inhibit the above effects. miR-29 can regulate PI3K/AMPK/PGC-1α/PPAR-γ signaling in microglial cells, promote their polarization to M2, and ultimately promote neovascularization in bladder cancer."

Journal • Bladder Cancer • Brain Cancer • CNS Tumor • Genito-urinary Cancer • Glioma • Oncology • Solid Tumor • HIF1A • MIR29A • MRC1 • PPARG

MicroRNA-29b involves in the progression of NAFLD to liver fibrosis (EASL-ILC 2023) - "Novel findings from demonstrate the essential role of miR-29b in preventing the progression of NAFLD to liver fibrosis."

Acute Myelogenous Leukemia • Fibrosis • Hepatology • Idiopathic Pulmonary Fibrosis • Immunology • Liver Cirrhosis • Liver Failure • Non-alcoholic Fatty Liver Disease • Pulmonary Disease • Respiratory Diseases • MIR29A • PPARA

The Role of MiR-29 in the Mechanism of Fibrosis. (PubMed, Mini Rev Med Chem) - "Finally, we review the antifibrotic activity of miR-29 mimicked in current studies and highlight miR-29 as a promising therapeutic reagent or target for the treatment of pulmonary fibrosis. Besides, there is an urgent need to screen and identify small compounds to modulate miR-29 expression in vivo."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • MIR29A • TGFB1

A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. (PubMed, EBioMedicine) - "Collectively, our results provide support for the development of the peptide-conjugated MRG-229 mimic as a potential therapy in humans with IPF."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • MIR29A • PDGFB • TGFB1

"5/n #MRG229 completely blunted In bleomycin-induced #PulmonaryFibrosis & we could use much ⬇️ doses, & give it SUBCUTANEOUSLY. It also goes to the 🫁 and is safe in rats and non-human primates! #ItWorks #ItWorkshttps://www.sciencedirect.com/science/article/pii/S2352396422004868" (@KaminskiMed)

Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Pulmonary Disease • Respiratory Diseases

Young Donor Adipose-Derived Mesenchymal Stem Cell Therapy Rescues Bleomycin-Induced Pulmonary Fibrosis in an Aged Mouse Model in Part Through Regulation of microRNAs (ATS 2022) - "Adipose-derived mesenchymal stromal cells may rescue bleomycin-induced lung fibrosis in aged mice via regulation of fibroblast-derived miR-29 and miR-199, suggesting possible therapy for chronic fibrotic lung disease."

Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • CAV1 • MIR29A • MMP2

Inhibiting effect of miR-29 on proliferation and migration of uterine leiomyoma via the STAT3 signaling pathway. (PubMed, Aging (Albany NY)) - "High expression of miR-29 could inhibit cell proliferation, invasion, and metastasis in uterine leiomyoma, which might be related to the inhibition of the STAT3 signaling pathway, and could provide a novel target for the treatment of uterine leiomyoma."

Journal • Gynecologic Cancers • Oncology • Solid Tumor • Uterine Leiomyoma • CCND1 • MIR29A • MMP2 • MMP9 • MYC • VIM

"Was the MRG 229 delivered through any delivery? nanoparticles?" (@LucasAr16078596)

Reversing the effects of pulmonary fibrosis with a microRNA mimic - "'The copy, when infused into the blood, goes to the lung and it has a maintained impact. We are extremely awed that it can reverse fibrosis, not just anticipate it,' said Naftali Kaminski, M.d....."

Media quote • Preclinical • Idiopathic Pulmonary Fibrosis

circFAM120A participates in repeated implantation failure by regulating decidualization via the miR-29/ABHD5 axis. (PubMed, FASEB J) - "Moreover, miR-29 mimics efficiently reduced ABHD5 expression levels and suppressed the decidualization process, whereas a miR-29 inhibitor partly rescued ABHD5 mRNA expression level and decidualization reduced by the knockdown of circFAM120A. Therefore, circFAM120A modulated decidualization in RIF through the miR-29/ABHD5 axis."

Journal • MIR29A

miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates (GlobeNewswire) - "Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data; additional NIH grant funding triggered....In June 2020, the Company hosted a key opinion leader (KOL) webcast...and reported additional preclinical rodent safety and in vitro human efficacy data for MRG-229....Anti-fibrotic activity of next-generation miR-29 mimics in mouse bleomycin-induced pulmonary fibrosis was observed for both intravenous and subcutaneous routes of administration....Based on these results, the Company has initiated a non-human primate toxicology study and expects to report additional preclinical safety and efficacy data before the end of 2020."

Grant • Preclinical • Idiopathic Pulmonary Fibrosis

"@KaminskiMed Dr., Do you know when the MRG 229 NPH toxicology testing started and estimated completion date?" (@SubpoenaedJudge)

miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis (Miragen Therapeutics Press Release) - "miRagen Therapeutics, Inc....today announced preclinical safety and efficacy data for MRG-229...in Idiopathic Pulmonary Fibrosis‎ (IPF)...demonstrated mechanistic biomarker regulation and antifibrotic activity in vitro using human model systems. In addition, subcutaneous administration of the product candidate induced the reversal of pathologic fibrotic gene expression and resulted in a significant reduction of fibrosis in the most commonly employed pre-clinical animal model of pulmonary fibrosis. Finally, high doses of MRG-229 in preclinical toxicology studies in rats showed no clinically significant toxicity,' stated William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics....'In our recently published analysis of fibrosis progression in the human lung, miR-29 emerged as a key regulator of fibrotic pathways in IPF,' said Naftali Kaminski, M.D."

Preclinical • Idiopathic Pulmonary Fibrosis

"3/n Rusty Montgomery @rmontonio of MiRagen: The Mir-29 mimic Remlarsen has hit fibrosis targets in a phase 1 trial of Keloid formation - a phase II trial is happening #AntiKeloid #CureScarring" (@KaminskiMed)

P1 data • P2 data • Fibrosis • Immunology

miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd (GlobeNewswire) - "miRagen Therapeutics, Inc....today announced it is scheduled to host a key opinion leaders (KOL) call regarding idiopathic pulmonary fibrosis (IPF) on Tuesday, June 23rd at 11 a.m. Eastern Time. The Company will also discuss encouraging new preclinical safety and efficacy data for its MRG-229 being developed for the treatment of IPF during the call....The KOLs will discuss the current and increasing unmet medical needs in treating patients with IPF....This program was recently awarded additional funds from an NIH/NHLBI CADET grant and Yale University."

Live event • Preclinical • Idiopathic Pulmonary Fibrosis

[VIRTUAL] Dicer Modulation as a Mechanism of Age related Dysfunction in Arteriogenesis (ATVB-PVD-GPM 2020) - "Transfection of macrophages with miR29 mimic increased VEGF-A expression...Our studies will lead to a paradigm shift from Dicer as a negative regulator of VEGF-A to that of a positive regulator. Moreover, the rescue of Dicer expression in aged macrophages may have profound implications in the development of novel treatment strategies that can promote arteriogenesis in the setting of severe age-related vasculopathies."

Gene Therapies • Ischemic stroke • Reperfusion Injury

A microRNA-29 mimic (remlarsen) represses extracellular matrix expression and fibroplasia in the skin. (PubMed, J Invest Dermatol) - "miR-29 mimics prevent pulmonary fibrosis in mouse models but have not previously been tested in the skin. Biomarker expression translated to clinical proof-of-mechanism; in a double-blinded, placebo-randomized, within-subject controlled clinical trial of single and multiple ascending doses of remlarsen in normal healthy volunteers, remlarsen repressed collagen expression and the development of fibroplasia in incisional skin wounds. These results suggest that remlarsen may be an effective therapeutic to prevent formation of a fibrotic scar (hypertrophic scar or keloid) or to prevent cutaneous fibrosis, such as scleroderma."

Biomarker • Journal

Miragen reports first quarter 2020 financial results and provides corporate update (Miragen Therapeutics Press Release) - "Idiopathic Pulmonary Fibrosis (MRG-229): miRagen expects to report additional preclinical safety and efficacy data for MRG-229 during the second quarter of 2020....Cutaneous and Ocular Fibrosis (Remlarsen): The Company is currently working to complete its analysis of the one-year primary endpoint data for its Phase 2 clinical trial of remlarsen. Due to the potential impact of the COVID-19 pandemic on clinical sites, the Company cannot accurately predict when it will report the final topline data from this clinical trial, which was previously expected to be released in the second half of 2020."

P2 data • Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Hypoxia-induced apoptosis of cardiomyocytes is restricted by ginkgolide B-downregulated microRNA-29. (PubMed, Cell Cycle) - "To construct miR-29-overexpressed cells, miR-29 mimic was transfected into H9c2 cells...Our results confirmed that ginkgolide B might have therapeutic significance by repressing hypoxic apoptosis. Ginkgolide B-elicited miR-29 inhibition might be the basis of this beneficial role."

IO Biomarker • Journal • Acute Coronary Syndrome • Cardiovascular • Gene Therapies • Genetic Disorders • Ischemic stroke • Myocardial Infarction • Reperfusion Injury • BCL2 • CASP3

Micro-RNA29b Enhances the Sensitivity of GlioblastomaMultiforme Cells to Temozolomide by Promoting Autophagy. (PubMed, Anat Rec (Hoboken)) - "miR-29b potentiates TMZ sensitivity against GBM cells by inducing autophagy and the combined use of miR-29 mimic and TMZ might represent a potential therapeutic strategy for GBM patients."

Journal • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

miRagen reports fourth quarter and full year 2019 financial results (GlobeNewswire) - "In December 2019, the Company announced that its preclinical pipeline development efforts will be primarily focused on the development of MRG-229 as a potential treatment for patients with IPF....miRagen expects to report additional preclinical safety and efficacy data for MRG-229 during the second quarter of 2020."

Preclinical